Asset acquisitions -Morphimmune (Details) $ / shares in Units, $ in Thousands		3 Months Ended	9 Months Ended
	Oct. 02, 2023 USD ($) $ / shares shares	Sep. 30, 2024 USD ($)	Sep. 30, 2024 USD ($)	Dec. 31, 2023 $ / shares
Asset acquisitions
Exercise price | $ / shares				$ 10.00
In-process research and development		$ 6,706	$ 124,972
Morphimmune Inc
Asset acquisitions
Number of shares issuable | shares	8,835,710
Exchange ratio	0.3042
Options to purchase shares of common stock | shares	2,472,563
Exercise price | $ / shares	$ 1.29
Consideration paid	$ 88,000
Transaction costs	800
Common stock issued	$ 72,500
IPO share price per share | $ / shares	$ 8.20
Contingent consideration related to the value of Morphimmune share-based awards	$ 14,700
In-process research and development	$ 80,800